<DOC>
	<DOC>NCT02320877</DOC>
	<brief_summary>In this prospective trial 50 patients, diagnosed with moderate to severe obstructive sleep apnea (OSA) (AHI &gt; 15/h sleep) will be included and treated with mandibular advancement devices (MAD). These patients will undergo cardiovascular examination; echocardiography and 24h-blood pressure monitoring, on top of the normal clinical evaluation of OSA patients. These cardiovascular examinations will take place before and during MAD therapy.</brief_summary>
	<brief_title>Evaluation of the Cardiovascular Effects of the MAS in the Treatment of Obstructive Sleep Apnea</brief_title>
	<detailed_description />
	<mesh_term>Sleep Apnea, Obstructive</mesh_term>
	<mesh_term>Methaqualone</mesh_term>
	<criteria>AHI &gt; 15 events/hour No other active OSA therapy in the 3 months preceding inclusion Willing to participate after informed consent Positive advice on OAT after DISE Insufficient teeth to support the device Periodontal problems including tooth mobility Active temporomandibular joint dysfunction Limited maximum protrusive capacity (&lt; 6 mm)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>